A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma
A multicenter, randomized, double-blind, parallel-controlled Phase III trial to evaluate the efficacy and safety of anotinib hydrochloride capsule combined with epirubicin hydrochloride versus placebo combined with epirubicin hydrochloride in first-line treatment of advanced soft tissue sarcoma
Soft Tissue Sarcoma
DRUG: Anlotinib hydrochloride capsule|DRUG: Epirubicin|DRUG: Arotinib hydrochloride capsule placebo
Progression free survival (PFS) assessed by independent review committees (IRC), Time from the first dose to the first documentation of progression disease (PD) or death from any cause, whichever occurs first, Baseline up to 12 months
Overall survival (OS), From randomization to the time of death from any cause, Baseline up to die|progression free survival (PFS) assessed by investigator, Time from the first dose to the first documentation of PD or death from any cause, whichever occurs first, Baseline up to 12 months|Objective response rate (ORR), The sum of percentage of participants with complete response rate and partial response rate, Baseline up to 6 months|Disease control rate (DCR), percentage of participants with complete response, partial response plus stable disease, Baseline up to 25 months|Duration of overall response (DOR), the time from the date of first documentation of a CR or PR to the date of first documentation of tumor progression, Baseline up to 6 months|Degradation rate, Proportion of patients with tumor regression meeting surgical resection criteria in each group during the study period, Baseline up to 6 months
A multicenter, randomized, double-blind, parallel-controlled Phase III trial to evaluate the efficacy and safety of anotinib hydrochloride capsule combined with epirubicin hydrochloride versus placebo combined with epirubicin hydrochloride in first-line treatment of advanced soft tissue sarcoma